-
Subject Areas on Research
-
7alpha,11beta-Dimethyl-19-nortestosterone: a potent and selective androgen response modulator with prostate-sparing properties.
-
A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.
-
A clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancer.
-
A glutaminase isoform switch drives therapeutic resistance and disease progression of prostate cancer.
-
A new prostate cancer therapeutic approach: combination of androgen ablation with COX-2 inhibitor.
-
A role for the androgen receptor in the treatment of male breast cancer.
-
A telomerase-immortalized primary human prostate cancer clonal cell line with neoplastic phenotypes.
-
Absence of a correlation of androgen receptor gene CAG repeat length and prostate cancer risk in an African-American population.
-
Actions of steroids in mitochondria.
-
Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells.
-
Aggressive fibromatosis (desmoid tumor) is a monoclonal disorder.
-
Agonist and antagonist switch DNA motifs recognized by human androgen receptor in prostate cancer.
-
An interdomain interaction of the androgen receptor is required for its aggregation and toxicity in spinal and bulbar muscular atrophy.
-
Androgen Receptor Splice Variant, AR-V7, as a Biomarker of Resistance to Androgen Axis-Targeted Therapies in Advanced Prostate Cancer.
-
Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens.
-
Androgen and estrogen treatment, alone or in combination, differentially influences bone maturation and hypothalamic mechanisms that time puberty in the male rhesus monkey (Macaca mulatta).
-
Androgen receptor activation by G(s) signaling in prostate cancer cells.
-
Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer.
-
Androgen receptor down-regulation in prostate cancer with phosphorodiamidate morpholino antisense oligomers.
-
Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663.
-
Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide.
-
Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer.
-
Androgen receptor splice variant AR3 promotes prostate cancer via modulating expression of autocrine/paracrine factors.
-
Androgen receptor variant-driven prostate cancer II: advances in clinical investigation.
-
Androgen receptor variant-driven prostate cancer II: advances in laboratory investigations.
-
Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting.
-
Androgen receptor with short polyglutamine tract preferably enhances Wnt/β-catenin-mediated prostatic tumorigenesis.
-
Androgen receptor-cofactor interactions as targets for new drug discovery.
-
Androgens regulate prostate cancer cell growth via an AMPK-PGC-1α-mediated metabolic switch.
-
Basal epithelial stem cells are efficient targets for prostate cancer initiation.
-
Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer.
-
Bisphenol A affects androgen receptor function via multiple mechanisms.
-
Bromodomain protein 4 discriminates tissue-specific super-enhancers containing disease-specific susceptibility loci in prostate and breast cancer.
-
CaM kinase kinase beta-mediated activation of the growth regulatory kinase AMPK is required for androgen-dependent migration of prostate cancer cells.
-
CaMKK2: a novel target for shaping the androgen-regulated tumor ecosystem.
-
Cadmium-induced neoplastic transformation of human prostate epithelial cells.
-
Cav1.3 channel α1D protein is overexpressed and modulates androgen receptor transactivation in prostate cancers.
-
Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth.
-
Characterization of androgen receptor in Sertoli cell-enriched testis.
-
Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model.
-
Chromatin accessibility reveals insights into androgen receptor activation and transcriptional specificity.
-
Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer.
-
Clinical Utility of Circulating Tumor Cells in Advanced Prostate Cancer.
-
Clinical results in cachexia therapeutics.
-
Cloning of human androgen receptor complementary DNA and localization to the X chromosome.
-
Combined effects of dietary phytoestrogen and synthetic endocrine-active compound on reproductive development in Sprague-Dawley rats: genistein and methoxychlor.
-
Controversies in the treatment of prostate cancer with maximal androgen deprivation.
-
Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes.
-
Copper signaling axis as a target for prostate cancer therapeutics.
-
Curcumin down-regulates AR gene expression and activation in prostate cancer cell lines.
-
DHX15 is up-regulated in castration-resistant prostate cancer and required for androgen receptor sensitivity to low DHT concentrations.
-
Definition of the cellular mechanisms which distinguish between hormone and antihormone activated steroid receptors.
-
Deletion of the p16INK4a tumor suppressor and expression of the androgen receptor induce sarcomatoid carcinomas with signet ring cells in the mouse prostate.
-
Development of a small-molecule serum- and glucocorticoid-regulated kinase-1 antagonist and its evaluation as a prostate cancer therapeutic.
-
Development of peptide antagonists for the androgen receptor using combinatorial peptide phage display.
-
Differences in steroid specificity for rat androgen binding protein and the cytoplasmic receptor.
-
Differential presentation of protein interaction surfaces on the androgen receptor defines the pharmacological actions of bound ligands.
-
Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13.
-
Dominant-negative androgen receptor inhibition of intracrine androgen-dependent growth of castration-recurrent prostate cancer.
-
Dynamic nucleosome landscape elicits a noncanonical GATA2 pioneer model.
-
EGFR-upregulated LIFR promotes SUCLG2-dependent castration resistance and neuroendocrine differentiation of prostate cancer.
-
ELF3 is a repressor of androgen receptor action in prostate cancer cells.
-
Editor' summary: A paradigm shift in castration-resistant prostate cancer management.
-
Enrichment of putative prostate cancer stem cells after androgen deprivation: upregulation of pluripotency transactivators concurs with resistance to androgen deprivation in LNCaP cell lines.
-
Enzalutamide in metastatic prostate cancer before chemotherapy.
-
Evaluation and treatment of male and female pattern hair loss.
-
Evaluation of chemicals with endocrine modulating activity in a yeast-based steroid hormone receptor gene transcription assay.
-
Evaluation of ligand-dependent changes in AR structure using peptide probes.
-
Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer.
-
Exemestane's 17-hydroxylated metabolite exerts biological effects as an androgen.
-
Expression, purification and primary crystallographic study of human androgen receptor in complex with DNA and coactivator motifs.
-
Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers.
-
Functional domain and motif analyses of androgen receptor coregulator ARA70 and its differential expression in prostate cancer.
-
Genetic alterations in prostate adenocarcinoma.
-
Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.
-
Gli Transcription Factors Mediate the Oncogenic Transformation of Prostate Basal Cells Induced by a Kras-Androgen Receptor Axis.
-
Glucocorticoids manifest androgenic activity in a cell line derived from a metastatic prostate cancer.
-
HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS.
-
Hormone control and expression of androgen receptor coregulator MAGE-11 in human endometrium during the window of receptivity to embryo implantation.
-
Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function.
-
Identification of a Novel Coregulator, SH3YL1, That Interacts With the Androgen Receptor N-Terminus.
-
Identification of a cell of origin for human prostate cancer.
-
Identification of differentially methylated genes in normal prostate tissues from African American and Caucasian men.
-
Immunohistochemical characterization of neuroendocrine cells in prostate cancer.
-
Increased androgen receptor gene copy number is associated with TMPRSS2-ERG rearrangement in prostatic small cell carcinoma.
-
Induction of Kruppel-like factor 5 expression by androgens results in increased CXCR4-dependent migration of prostate cancer cells in vitro.
-
Influence of E. coli-induced prostatic inflammation on expression of androgen-responsive genes and transforming growth factor beta 1 cascade genes in rats.
-
Inhibiting androgen receptor nuclear entry in castration-resistant prostate cancer.
-
Inhibition of androgen receptor-dependent transcriptional activity by DDT isomers and methoxychlor in HepG2 human hepatoma cells.
-
Inhibition of prostate cancer cell growth by second-site androgen receptor antagonists.
-
Inhibition of the androgen receptor induces a novel tumor promoter, ZBTB46, for prostate cancer metastasis.
-
Integrated analysis identifies a class of androgen-responsive genes regulated by short combinatorial long-range mechanism facilitated by CTCF.
-
Interaction of methoxychlor and related compounds with estrogen receptor alpha and beta, and androgen receptor: structure-activity studies.
-
International Union of Pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors.
-
Invasive prostate carcinoma driven by c-Src and androgen receptor synergy.
-
LINC00675 activates androgen receptor axis signaling pathway to promote castration-resistant prostate cancer progression.
-
LRIG1 is a pleiotropic androgen receptor-regulated feedback tumor suppressor in prostate cancer.
-
Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast.
-
Leukemia Inhibitory Factor Promotes Castration-resistant Prostate Cancer and Neuroendocrine Differentiation by Activated ZBTB46.
-
Ligand-specific dynamics of the androgen receptor at its response element in living cells.
-
Linking ligand-induced alterations in androgen receptor structure to differential gene expression: a first step in the rational design of selective androgen receptor modulators.
-
Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses.
-
Loss of MyD88 leads to more aggressive TRAMP prostate cancer and influences tumor infiltrating lymphocytes.
-
Loss of SPDEF and gain of TGFBI activity after androgen deprivation therapy promote EMT and bone metastasis of prostate cancer.
-
Loss of androgen signaling in mesenchymal sonic hedgehog responsive cells diminishes prostate development, growth, and regeneration.
-
Loss of the tumor suppressor, Tp53, enhances the androgen receptor-mediated oncogenic transformation and tumor development in the mouse prostate.
-
Lysophosphatidic acid promotes survival of androgen-insensitive prostate cancer PC3 cells via activation of NF-kappaB.
-
MMTV-PyMT and Derived Met-1 Mouse Mammary Tumor Cells as Models for Studying the Role of the Androgen Receptor in Triple-Negative Breast Cancer Progression.
-
Management of men with metastatic castration-resistant prostate cancer following potent androgen receptor inhibition: a review of novel investigational therapies.
-
Mapping of m6A and Its Regulatory Targets in Prostate Cancer Reveals a METTL3-Low Induction of Therapy Resistance.
-
Molecular biology and function of the androgen receptor in genital development.
-
Molecular determinants for enzalutamide-induced transcription in prostate cancer.
-
Molecular implications of the antiandrogen withdrawal syndrome.
-
Molecular mechanisms of development of the human fetal female reproductive tract.
-
Morphologic Spectrum of Neuroendocrine Tumors of the Prostate: An Updated Review.
-
Mutant and wild-type androgen receptors exhibit cross-talk on androgen-, glucocorticoid-, and progesterone-mediated transcription.
-
New treatment options in castration-resistant prostate cancer.
-
Novel chemotherapies in development for management of castration-resistant prostate cancer.
-
Ornithine Decarboxylase Is Sufficient for Prostate Tumorigenesis via Androgen Receptor Signaling.
-
PC3 is a cell line characteristic of prostatic small cell carcinoma.
-
Pharmacological blockade of a β(2)AR-β-arrestin-1 signaling cascade prevents the accumulation of DNA damage in a behavioral stress model.
-
Pharmacological uncoupling of androgen receptor-mediated prostate cancer cell proliferation and prostate-specific antigen secretion.
-
Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer.
-
Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer.
-
Phospho-MED1-enhanced UBE2C locus looping drives castration-resistant prostate cancer growth.
-
Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk.
-
Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy.
-
Precision Medicine Approaches When Prostate Cancer Akts Up.
-
Preclinical and Coclinical Studies in Prostate Cancer.
-
Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer.
-
Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study.
-
Prostate Cancer Disseminated Tumor Cells are Rarely Detected in the Bone Marrow of Patients with Localized Disease Undergoing Radical Prostatectomy across Multiple Rare Cell Detection Platforms.
-
Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting Summary.
-
Prostate biopsies from black men express higher levels of aggressive disease biomarkers than prostate biopsies from white men.
-
Prostate epithelial cell of origin determines cancer differentiation state in an organoid transformation assay.
-
Prostate. III--A structural feature characteristic of the rat prostate 5 alpha-reductase active site.
-
Protein Arginine Methyltransferase 5 Promotes pICln-Dependent Androgen Receptor Transcription in Castration-Resistant Prostate Cancer.
-
Proteome-wide muscle protein fractional synthesis rates predict muscle mass gain in response to a selective androgen receptor modulator in rats.
-
R726L androgen receptor mutation is uncommon in prostate cancer families in the united states.
-
Rare and low-frequency coding variants alter human adult height
-
Reduced prostate branching morphogenesis in stromal fibroblast, but not in epithelial, estrogen receptor α knockout mice.
-
Reply to L. Dirix, B. De Laere et al, and A. Sharp et al.
-
Role of autonomous androgen receptor signaling in prostate cancer initiation is dichotomous and depends on the oncogenic signal.
-
Salivary testosterone and a trinucleotide (CAG) length polymorphism in the androgen receptor gene predict amygdala reactivity in men.
-
Sexually dimorphic fin regeneration in zebrafish controlled by androgen/GSK3 signaling.
-
Shaping Chromatin States in Prostate Cancer by Pioneer Transcription Factors.
-
Small-Molecule-Mediated Degradation of the Androgen Receptor through Hydrophobic Tagging.
-
Steroid structural requirements for high affinity binding to human sex steroid binding protein (SBP).
-
Stromal androgen signaling acts as tumor niches to drive prostatic basal epithelial progenitor-initiated oncogenesis.
-
Stromal epigenetic dysregulation is sufficient to initiate mouse prostate cancer via paracrine Wnt signaling.
-
Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials).
-
Systematic dissection of phenotypic, functional, and tumorigenic heterogeneity of human prostate cancer cells.
-
TET2 binds the androgen receptor and loss is associated with prostate cancer.
-
Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012.
-
Targeting RET Kinase in Neuroendocrine Prostate Cancer.
-
Testosterone induction of song in photosensitive and photorefractory male sparrows.
-
Testosterone regulation of Akt/mTORC1/FoxO3a signaling in skeletal muscle.
-
Testosterone supplementation upregulates androgen receptor expression and translational capacity during severe energy deficit.
-
The Molecular Taxonomy of Primary Prostate Cancer.
-
The androgen receptor CAG and GGN repeat polymorphisms and prostate cancer susceptibility in African-American men: results from the Flint Men's Health Study.
-
The homeodomain protein HOXB13 regulates the cellular response to androgens.
-
The oncogenomic function of androgen receptor in esophageal squamous cell carcinoma is directed by GATA3.
-
The polymorphic exon 1 androgen receptor CAG repeat in men with a potential inherited predisposition to prostate cancer.
-
The production of androgen binding protein by Sertoli Cells.
-
The role of AR-V7 testing in the management of metastatic CRPC.
-
The role of N-cadherin/c-Jun/NDRG1 axis in the progression of prostate cancer.
-
The role of testosterone in coordinating male life history strategies: The moderating effects of the androgen receptor CAG repeat polymorphism.
-
The urology perspective on expanding androgen-targeted treatments for men with castration-resistant prostate cancer.
-
Therapeutic potential of ReACp53 targeting mutant p53 protein in CRPC.
-
Three-tiered role of the pioneer factor GATA2 in promoting androgen-dependent gene expression in prostate cancer.
-
Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance.
-
Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity.
-
Trinucleotide repeat polymorphisms in the androgen receptor gene and risk of ovarian cancer.
-
Tumor Repression of VCaP Xenografts by a Pyrrole-Imidazole Polyamide.
-
Upregulation of VEGF-C by androgen depletion: the involvement of IGF-IR-FOXO pathway.
-
Use of phage display to identify novel mineralocorticoid receptor-interacting proteins.
-
Using circulating tumor cells to inform on prostate cancer biology and clinical utility.
-
Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer.
-
Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity.
-
Keywords of People
-
Berchuck, Andrew,
James M. Ingram Distinguished Professor of Gynecologic Oncology,
Obstetrics and Gynecology, Gynecologic Oncology
-
McDonnell, Donald Patrick,
Glaxo-Wellcome Distinguished Professor of Molecular Cancer Biology, in the School of Medicine,
Cell Biology
-
Moorman, Patricia Gripka,
Professor Emeritus in Family Medicine and Community Health,
Duke Cancer Institute